Objective: We explored how investigators of ongoing or planned trials respond to the publication of a trial stopped early for benefit addressing a similar question.
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Transparency declaration: Dr Murad affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. Further, the majority of published truncated trials fail to adequately report at least one important factor regarding the decision to stop early; such as the planned sample size, details of interim analyses, whether a stopping rule informed the decision to stop, or whether the analysis was adjusted to account for interim monitoring and truncation. (2) Misleading overestimates from truncated trials seriously threaten the integrity of decisions made by patients and clinicians when they trade off the benefits and harms of interventions. Unfortunately, the majority (71%) of systematic reviews that included truncated trials did not comment or recognize this possible bias.(4) Simulation studies have shown that when trials stopped early for benefit are included in a meta-analysis, the pooled effect size and heterogeneity parameters become distorted.(5) Therefore, this issue affects the synthesis of evidence and subsequent decision making that depends on systematic reviews, such as guidelines. The motivation to stop a trial early for benefit should be balanced against the risk of disseminating overestimated treatment effect. It should also be balanced against the loss of the opportunity to generate more precise evidence and opportunity to capture the effect of treatment on secondary outcomes and outcomes that require longer follow up (particularly adverse effects). If stopping a trial early for benefit was the correct decision (ie, it would be unethical to continue the trial); then the conduct of subsequent trials addressing the same question (subsequent trials) would also be unethical.
Several justifiable reasons for launching subsequent trials are plausible. First, researchers may want to test the intervention in a population or setting that are somewhat different from that of a truncated trial. Second, researchers may be skeptic about the results of the truncated trials (because the trial was small or at high risk of bias). Third, researchers may be interested in knowing the effect of the treatment on other outcomes.
If investigators, the clinical community, and ethics committees sanction subsequent trials, it raises serious questions regarding the initial decision to truncate the M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 original trials for benefit. To explore the incidence of and rationale for subsequent trials, we conducted a meta-epidemiological study addressing how often subsequent trials were launched or continued after the publication of a truncated trial asking the same or similar research question.
METHODS/DESIGN
The protocol of this study has been published and provides further details. 
Study selection
We used online reference management systematic review software (DistillerSR, Evidence Partners, Ottawa, Canada; http://systematic-review.net/) to facilitate study selection. Pairs of independent reviewers screened the abstracts and then the full text version of potential references. Disagreements during abstract screening were included for full text screening and disagreements during full text screening were resolved by discussion or adjudication by a third reviewer. Agreement among reviewers on study selection using the kappa statistic averaged 0.71.
Data collection
Reviewers first judged whether patients, interventions, comparators, and outcomes of each subsequent trial matched those of the corresponding truncated trial using the same criteria established in a previous study (STOPIT-2, closeness rated on a 4-point Likert scale that ranged from 0-3).(3) Trials receiving the lowest similarity score for their population or intervention were excluded. Agreement among reviewers averaged 0.70 on the closeness criteria for patient population, interventions, comparators, and outcomes. Using standardized, pilot-tested data extraction forms and a detailed instruction manual, pairs of reviewers extracted data from eligible articles independently and in duplicate. We extracted subsequent trial characteristics (e.g. dates of enrollment and publication), whether a subsequent trial cited the corresponding truncated trial and M A N U S C R I P T
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10 the rationale for launching or continuing the subsequent trial despite knowing the results of the truncated trial. We also extracted data on whether subsequent trials provided a sample size calculation, whether sample size calculation was informed by truncated trial results, whether a data monitoring committee (DMC) was available, whether truncated trial publication led to a change in the subsequent trial protocol (e.g., interim analysis, unblinding), and congruence between truncated trial and subsequent trial results with respect to the direction of effect and statistical significance.
Pairs of reviewers assessed risk of bias, independently and in duplicate, of truncated trials using items from the Cochrane risk-of-bias tool (9) focusing on allocation concealment, blinding, and loss to follow-up. For all phases of data abstraction and risk of bias adjudication, reviewers resolved disagreements by discussion or, if necessary, by third party adjudication.
Outcomes of interest and statistical analysis
The main outcome of interest was the incidence of subsequent trials (proportion of truncated trials that were followed by at least one subsequent trial). We conducted multiple Poisson and logistic regression analysis to explore the extent to which the following a priori established variables were associated with the decision to conduct a subsequent trial: sample size, number of events, funding source (non-profit/government vs. for-profit), allocation concealment (yes vs. no/unclear), patient blinding (yes vs. no/unclear), provider blinding (yes vs. no/unclear), presence of a DMC (yes vs. no/unclear), the explicit use of a stopping rule (yes vs. no/unclear), and time since publication of truncated trial (time from the publication year of truncated trial to 2015).
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These variables were explored as potential confounders in regression. Poisson regression was used when the dependent outcome was the number of subsequent trials. Multiple logistic regression was used when the dependent outcome was "no subsequent trials published" vs "at least one subsequent trial published". We conducted sensitivity analysis to evaluate truncated trials published later than 1990. We hypothesized using this arbitrary date as a cutoff that the reporting and conducting of randomized trials have improved over time; particularly after guidelines for reporting trials have been implemented by many journals. A two tailed p-value <0.05 was regarded as being statistically significant. All statistical analyses were conducted using Stata version 14.0 (StataCorp LP, College Station, TX).
RESULTS:
The literature search yielded 3,217 potential subsequent trials, of which 262 proved eligible (figure 1 of the supplement). Overall, reviewers judged subsequent trial questions to be similar to truncated trial questions. On a 4-point scale where 3 is most similar, similarity or closeness scores of the patient, intervention, comparison and outcome averaged 2.25, 2.39, 2.52 and 2.50; respectively. Subsequent trials were published on average 4 years after corresponding truncated trials. Table 1 Overall, 102/207 (49%; 95% confidence interval 42%-56%) of truncated trials were followed by at least one subsequent trial addressing a similar question. The majority of truncated trials that were followed by subsequent trials had more than one related subsequent trial (56/102, 55%); median 2 (range 1-13). The characteristics of truncated trials are provided in table 1. The most common clinical areas addressed in these trials were cardiology (25%), cancer/malignancy (21%), human immunodeficiency virus infections (12%) and critical care (7%). In general, subsequent trials did not consider results of a truncated trial for sample size calculation or analysis plan. Only rarely did the publication of a truncated trial lead to the subsequent trial undergoing an interim analysis, breaking randomization codes or stopping early (4% of subsequent trials conducted interim analysis and 3% were M A N U S C R I P T
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presented an explicit sample size calculation.
The results of subsequent trials were compared to those of truncated trials in terms of the outcome used to justify early stopping in truncated trials. The treatment effect favored the opposite intervention compared to the truncated trial in 12% of the trials (statistically significant in 1%, and non-significant in 11%).
An illustrative example of a truncated trial and corresponding subsequent trials is presented in Table 3 . Abbreviations: RR, relative risk; CI, confidence interval; ICU, intensive care unit *Additional subsequent trials on this topic exist; however, we only describe here trials with more than 500 randomized patients.
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Poisson regression and logistic regression
Poisson regression and logistic regression demonstrated a statistically significant association between the incidence of subsequent trials and the time since the publication of the truncated trial suggesting that the longer the time since the truncated trial was published, the more subsequent trials were published. We did not find statistically significant associations between publication of subsequent trials and all other pre-specified explanatory (independent) variables (characteristics of truncated trials such as risk of bias, sample size, number of events, funding, presence of a DMC, and the explicit use of a stopping rule) ( Table 4) . 
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Sensitivity analysis
When we excluded truncated trials published earlier than 1990, the conclusions remain unchanged. Ninety /190 (47%; 95% confidence interval 40%-55%) of truncated trials were M A N U S C R I P T
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DISCUSSION
Previous empirical studies have demonstrated that the practice of stopping trials early for benefit is increasing over time, that many of these trials do not report a rigorous approach for the decision to stop, that many exaggerate treatment effects by up to one third, and that when sample sizes and number of events are modest, the overestimates may be very large. (3) In the current study we found that 49% of truncated trials were followed by subsequent trials. In only a minority of these did investigators provide a rationale for randomizing patients despite the prior truncated trial, and in only a minority of these did the investigators suggest that findings required replication in an appreciably different population or setting.
The strengths of this study include a systematic and extensive literature search About half of the randomized controlled trials stopped early for benefit were followed by subsequent trials addressing a similar question
Trialists of subsequent trials may have been skeptic about the decision to stop prior trials; thus pursuing their own trials about the same question
There were no characteristics of truncated trials that were associated with, or could predict launching subsequent trials A more rigorous threshold for stopping early for benefit is needed
